By Daniella Parra
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), said it enhanced its SQore platform with four new patents and two notices of allowance.
The additions, spanning the U.S., Canada, South Korea and India, will strengthen the proprietary viscosity-reducing components in Comera’s SQore platform and extend previously granted patent claims, the company said in a statement.
Comera facilitates the subcutaneous (SQ) administration of intravenous (IV) medications, including monoclonal antibodies (mAbs), it said.
“We have expanded and strengthened our robust global patent portfolio this year, and these new patents underscore our commitment to innovation and enhance our partnership and pipeline strategy,” said CEO Jeffrey Hackman. “This accomplishment reiterates our position as the trusted partner for developing subcutaneous product formulations which have the potential to improve patient access and ease of use for important biologics.”